Perdoceo is already shifting toward graduate health sciences. After acquiring the University of St. Augustine for Health Sciences in December 2024, the company has been building a broader health-sciences platform while maintaining a strong balance sheet and an FY2026 adjusted operating-income outlook of $258 million to $263 million. South University is a direct extension of that strategy rather than a move into an unrelated market.
The deal materially broadens Perdoceo’s clinical-program footprint. South brings approximately 10,500 students, $291 million of 2025 revenue and $34.0 million of 2025 adjusted operating income, with physician assistant, anesthesiologist assistant, pharmacy and nursing programs among its core offerings. (Transaction Details) Management says the acquisition will “firmly establish” Perdoceo’s graduate health-sciences offerings. 〔0〕 (South University overview)
| Metric | Filing figure |
|---|---|
| Cash paid at closing | $130M–$150M (Transaction Details) |
| Deferred consideration | $18M over 24 months (Transaction Details) |
| Maximum earn-out | Up to $56M tied to 2027–2029 EBITDA thresholds (Transaction Details) |
| Potential total consideration | Up to $204M–$224M (calculated from Transaction Details) |
| South 2025 revenue | Approximately $291M (Transaction Details) |
| South 2025 adjusted operating income | Approximately $34.0M (Transaction Details) |
| Perdoceo FY2026 adjusted operating-income outlook | $258M–$263M (Affirming Outlook) |
The economics are meaningful, but not fully proven. The maximum consideration is roughly 6.0x–6.6x South’s 2025 adjusted operating income, although the earn-out is performance-based and may not be paid in full. Perdoceo expects the transaction to be immediately accretive to adjusted operating income beginning in 2027, but that benefit is management’s forecast rather than a current result. 〔1〕 (Transaction Details)
Funding is manageable, but the purchase uses capital that could otherwise support buybacks or dividends. The transaction has no financing condition and will be funded with cash on hand. 〔2〕 (Transaction Details) Perdoceo reported $643.5 million of cash, cash equivalents, restricted cash and short-term investments at December 31, 2025, while also describing acquisitions, dividends and repurchases as competing capital-allocation priorities. That makes the deal fundable, but not costless from a shareholder-return perspective.
The deal is announced, not closed. Completion requires regulatory and accreditor approvals, and South will be converted from nonprofit to for-profit status. The company targets closing as early as April 2027, with a July 9, 2027 termination deadline and potential termination fees of up to $20 million. 〔3〕 (Transaction overview) 〔4〕 (Transaction overview) This leaves execution, accreditation and ownership-conversion risk between today’s strategic announcement and the expected earnings contribution.
Bottom line: This is a substantive, strategically aligned acquisition that accelerates Perdoceo’s graduate-health-sciences buildout and adds a stated 2027 earnings contributor. The positive read is tempered by a sizable cash commitment and the fact that regulatory approvals and conversion work still stand between signing and delivery.
Read the original 8-K on SEC EDGAR ↗